News | Atrial Fibrillation | December 07, 2023

Ajax Health Establishes Cortex, a Comprehensive AFib Ablation Technology Company, with $90 Million Investment Led by KKR and Hellman and Friedman

Cortex's fully integrated solution will include advanced diagnostic and therapeutic pulsed field ablation catheters supported by innovative mapping technology

Cortex's fully integrated solution will include advanced diagnostic and therapeutic pulsed field ablation catheters supported by innovative mapping technology.

December 7, 2023 — Ajax Health announced today the formation and funding of Cortex, a medical technology company developing an integrated mapping and ablation solution suite for the treatment of atrial fibrillation (AFib), the most common heart rhythm disorder, affecting more than 30 million patients worldwide. Cortex has raised $90 million in funding commitments led by KKR and Hellman & Friedman (H&F) with participation by other investors including AI Life Sciences, an affiliate of Access Industries.

Cortex brings together expert teams with complementary innovations in electrophysiology to accelerate the continued development and clinical validation of next-generation ablation solutions and differentiated AFib mapping technology. The fully integrated solution suite is designed to enable more precise therapy planning and delivery and optimize clinical outcomes and safety for AFib patients, while simplifying workflows and improving procedural efficiency.

"Cortex's vision is to enable more intelligent AFib treatment," said Duke Rohlen, CEO of Ajax Health and CEO of Cortex. "We are developing solutions that prioritize precision, simplicity, and efficiency to simultaneously improve patient outcomes and lower procedural cost."

Cortex is focused on developing diagnostic and pulsed field ablation catheters with a comprehensive mapping and navigation solution powered by Ablacon's innovative Electrographic Flow® (EGF) mapping technology. EGF mapping allows physicians to detect AFib sources and is designed to support personalized ablation therapy to potentially improve outcomes. The recently completed randomized, controlled FLOW-AF trial (NCT04473963) showed that EGF-guided treatment of AFib sources in persistent AFib patients improved freedom from AFib at one year post-ablation by 51% on an absolute basis compared with patients randomized to control, who received conventional pulmonary vein isolation therapy only. Ablacon's latest Ablamap X mapping system is 510(k) cleared. Following on the favorable results of FLOW-AF, the company has launched the RESOLVE-AF trial (NCT05883631), a large, international, multi-center clinical trial to further evaluate benefits in AFib patients and support CE mark application. 

“Duke Rohlen and the Ajax team have cultivated an exceptional ecosystem of engineers and clinical experts with a clear plan to bring impactful new technology to clinical settings,” said Ali Satvat, Partner, Co-Head of Americas Health Care and Global Head of Health Care Strategic Growth at KKR. “We are pleased to continue our long-standing strategic partnership with Duke and join with a strong investor group to support Cortex as it pursues improved outcomes for cardiac arrhythmia patients.”

KKR and H&F are investing in Cortex through the Cordis Accelerator, Cordis-X, which was established in 2021 as part of their investment in Cordis, a leading provider of cardiovascular and endovascular medical devices. KKR is investing additional capital in Cortex through its Health Care Strategic Growth Fund II.

For more information: https://www.ajaxhealth.com/


Related Content

News | Cardiovascular Business

June 11, 2024 — Columbia University Irving Medical Center’s CUIMC Division of Cardiology has launched the Mitral and ...

Home June 11, 2024
Home
Feature | Cardiovascular Business

June 7, 2024 — It is with great sadness that the Diagnostic and Interventional Cardiology (DAIC) team has learned of the ...

Home June 07, 2024
Home
News | Cardiovascular Business

June 5, 2024 — Edwards Lifesciences announced it has entered into a definitive agreement to sell its Critical Care ...

Home June 05, 2024
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Here is a look at the Top 10 pieces of content viewers were reading during the month of May. 1. American College of ...

Home June 04, 2024
Home
News | Cardiovascular Business

May 31, 2024 — Johnson & Johnson announced it has completed its acquisition of Shockwave Medical. Shockwave is now part ...

Home May 31, 2024
Home
News | Cardiovascular Business

May 22, 2024 — Voiant (USA) and Thirona (The Netherlands) announced they have entered a global commercial partnership ...

Home May 22, 2024
Home
News | Cardiovascular Business

May 14, 2024 — GE HealthCare, a leading global medical technology, pharmaceutical diagnostics and digital solutions ...

Home May 14, 2024
Home
News | Cardiovascular Business

May 6, 2024 — SMT (Sahajanand Medical Technologies), a leading medical device company at the forefront of innovative ...

Home May 06, 2024
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Clinical trials and innovative technology took center stage during the month of April, racking up some record number ...

Home May 03, 2024
Home
News | Cardiovascular Business

April 29, 2024 — Efforts by the American College of Cardiology, the American Heart Association, the Heart Failure ...

Home April 29, 2024
Home
Subscribe Now